Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TPTX, AVIR, QQQ, XBI, SPY, and represent 28.19% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 10 stocks: AVIR (+$260M), QQQ (+$235M), OLMA (+$148M), XBI (+$141M), CCCC (+$80M), BCAB (+$75M), TARS (+$70M), PRAX (+$58M), FMTX (+$38M), ALGS (+$35M).
- Started 24 new stock positions in BLSA, OLMA, Miragen Therapeutics, REPL, TARS, PRAX, QQQ, BCAB, HLXA, IMV. CEREW, CCCC, SWTX, AVIR, XFOR, FDMT, MASS, NTLA, SBTX, FHTX, ALGS, Tokai Pharmaceuticals, GLTO, FVAM.
- Reduced shares in these 10 stocks: Myokardia (-$61M), Eidos Therapeutics (-$50M), TWST (-$39M), TRIL (-$36M), ARCT (-$30M), CCXI (-$28M), GLPG (-$19M), CRSP (-$15M), OMER (-$14M), SRNE (-$14M).
- Sold out of its positions in AMRN, ARCT, AVEO, Eidos Therapeutics, GLPG, FIXX, KZR, Myokardia, OTLKW, TRIL.
- Cormorant Asset Management was a net buyer of stock by $936M.
- Cormorant Asset Management has $4.2B in assets under management (AUM), dropping by 61.58%.
- Central Index Key (CIK): 0001583977
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cormorant Asset Management
Companies in the Cormorant Asset Management portfolio as of the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Turning Point Therapeutics I (TPTX) | 6.9 | $292M | -2% | 2.4M | 121.85 | |
| Atea Pharmaceuticals (AVIR) | 6.2 | $260M | NEW | 6.4M | 40.53 | |
| Invesco Qqq Tr Unit Ser 1 Put Option (QQQ) | 5.6 | $235M | NEW | 750k | 313.74 | |
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 5.0 | $211M | +200% | 1.5M | 140.78 | |
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 4.4 | $187M | 500k | 373.88 | ||
| Bridgebio Pharma (BBIO) | 3.8 | $161M | 2.3M | 71.11 | ||
| Forma Therapeutics Hldgs SHS (FMTX) | 3.7 | $156M | +31% | 4.5M | 34.90 | |
| Olema Pharmaceuticals (OLMA) | 3.5 | $148M | NEW | 3.2M | 46.37 | |
| Apellis Pharmaceuticals (APLS) | 2.5 | $107M | 1.9M | 57.20 | ||
| Revolution Medicines (RVMD) | 2.4 | $99M | -5% | 2.5M | 39.59 | |
| Ishares Tr Russell 2000 Etf Put Option (IWM) | 2.3 | $98M | 500k | 196.06 | ||
| Stoke Therapeutics (STOK) | 2.1 | $89M | -6% | 1.4M | 61.93 | |
| Y Mabs Therapeutics (YMAB) | 2.0 | $82M | +18% | 1.7M | 49.51 | |
| C4 Therapeutics Com Stk (CCCC) | 1.9 | $80M | NEW | 2.5M | 32.14 | |
| Alx Oncology Hldgs (ALXO) | 1.8 | $76M | -9% | 882k | 86.20 | |
| Beam Therapeutics (BEAM) | 1.8 | $76M | +16% | 924k | 81.64 | |
| Bioatla (BCAB) | 1.8 | $75M | NEW | 2.3M | 32.90 | |
| Rocket Pharmaceuticals (RCKT) | 1.8 | $75M | 1.4M | 54.84 | ||
| Chemocentryx (CCXI) | 1.8 | $74M | -27% | 1.2M | 61.92 | |
| Immunovant (IMVT) | 1.7 | $72M | -4% | 1.6M | 46.19 | |
| Omeros Corporation (OMER) | 1.7 | $71M | -16% | 5.0M | 14.29 | |
| Mirati Therapeutics (MRTX) | 1.7 | $71M | +18% | 325k | 219.64 | |
| Tarsus Pharmaceuticals (TARS) | 1.7 | $70M | NEW | 1.7M | 40.81 | |
| Avidity Biosciences Ord (RNA) | 1.5 | $63M | 2.5M | 25.52 | ||
| Reata Pharmaceuticals Cl A (RETA) | 1.5 | $62M | +11% | 500k | 123.62 | |
| Praxis Precision Medicines I (PRAX) | 1.4 | $58M | NEW | 1.1M | 53.75 | |
| Zymeworks (ZYME) | 1.3 | $57M | +4% | 1.2M | 47.26 | |
| Acceleron Pharma (XLRN) | 1.3 | $54M | -15% | 425k | 127.94 | |
| Igm Biosciences (IGMS) | 1.3 | $53M | +166% | 600k | 88.29 | |
| Viela Bio | 1.2 | $51M | -9% | 1.4M | 35.97 | |
| Myovant Sciences (MYOV) | 1.1 | $47M | -20% | 1.7M | 27.62 | |
| Biohaven Pharmaceutical Holding (BHVN) | 0.9 | $36M | -15% | 425k | 85.71 | |
| Axonics Modulation Technolog (AXNX) | 0.8 | $35M | 693k | 49.92 | ||
| Aligos Therapeutics (ALGS) | 0.8 | $35M | NEW | 1.3M | 27.21 | |
| Twist Bioscience Corp (TWST) | 0.8 | $32M | -55% | 225k | 141.29 | |
| Sorrento Therapeutics Com New (SRNE) | 0.7 | $31M | -30% | 4.5M | 6.83 | |
| Crispr Therapeutics Namen Akt (CRSP) | 0.7 | $31M | -33% | 200k | 153.11 | |
| 908 Devices (MASS) | 0.7 | $30M | NEW | 545k | 54.10 | |
| Galecto (GLTO) | 0.6 | $27M | NEW | 2.2M | 12.30 | |
| Zai Lab Adr (ZLAB) | 0.6 | $26M | 189k | 135.34 | ||
| Blueprint Medicines (BPMC) | 0.6 | $25M | -18% | 225k | 112.15 | |
| Cabaletta Bio (CABA) | 0.6 | $24M | -7% | 1.9M | 12.48 | |
| Silverback Therapeutics (SBTX) | 0.6 | $23M | NEW | 500k | 46.34 | |
| Biontech Se Sponsored Ads (BNTX) | 0.5 | $22M | -15% | 275k | 81.52 | |
| Agenus Com New (AGEN) | 0.5 | $22M | -17% | 7.0M | 3.18 | |
| Tokai Pharmaceuticals | 0.5 | $21M | NEW | 1.4M | 15.09 | |
| Kura Oncology (KURA) | 0.5 | $21M | +30% | 650k | 32.66 | |
| Foghorn Therapeutics (FHTX) | 0.5 | $20M | NEW | 1.0M | 20.27 | |
| Akero Therapeutics (AKRO) | 0.5 | $19M | -13% | 743k | 25.80 | |
| Inspire Med Sys (INSP) | 0.4 | $19M | -16% | 100k | 188.09 | |
| Albireo Pharma (ALBO) | 0.4 | $19M | -28% | 500k | 37.51 | |
| Otonomy (OTIC) | 0.4 | $17M | -19% | 2.6M | 6.47 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.4 | $17M | -20% | 100k | 166.78 | |
| Intellia Therapeutics Put Option (NTLA) | 0.4 | $16M | NEW | 300k | 54.40 | |
| Axsome Therapeutics (AXSM) | 0.4 | $16M | -20% | 200k | 81.47 | |
| Tcr2 Therapeutics Inc cs (TCRR) | 0.4 | $16M | -16% | 500k | 30.93 | |
| Anaptysbio Inc Common (ANAB) | 0.3 | $14M | 650k | 21.50 | ||
| Pliant Therapeutics (PLRX) | 0.3 | $14M | 611k | 22.72 | ||
| Sarepta Therapeutics (SRPT) | 0.3 | $12M | -17% | 70k | 170.49 | |
| Deciphera Pharmaceuticals (DCPH) | 0.3 | $11M | -20% | 200k | 57.07 | |
| Repare Therapeutics Ord (RPTX) | 0.2 | $10M | -13% | 300k | 34.30 | |
| Health Sciences Acq Corp 2 Ord Shs (HSAQ) | 0.2 | $10M | 800k | 12.81 | ||
| Iteos Therapeutics (ITOS) | 0.2 | $10M | -14% | 300k | 33.82 | |
| Insmed Com Par $.01 (INSM) | 0.2 | $10M | -14% | 300k | 33.29 | |
| Akouos (AKUS) | 0.2 | $9.9M | 500k | 19.83 | ||
| Theravance Biopharma (TBPH) | 0.2 | $9.8M | -15% | 550k | 17.77 | |
| Harpoon Therapeutics (HARP) | 0.2 | $9.5M | 571k | 16.61 | ||
| Bctg Acquisition Corp (BCTG) | 0.2 | $9.2M | 800k | 11.44 | ||
| Springworks Therapeutics (SWTX) | 0.2 | $9.1M | NEW | 125k | 72.52 | |
| Uniqure Nv SHS (QURE) | 0.2 | $9.0M | -23% | 250k | 36.13 | |
| Argenx Se Sponsored Adr (ARGX) | 0.2 | $8.8M | -25% | 30k | 294.10 | |
| Protara Therapeutics Com Stk (TARA) | 0.2 | $8.5M | -22% | 350k | 24.21 | |
| 4d Molecular Therapeutics In (FDMT) | 0.2 | $8.3M | NEW | 200k | 41.45 | |
| Gossamer Bio (GOSS) | 0.2 | $8.2M | +241% | 848k | 9.67 | |
| Quotient SHS (QTNT) | 0.2 | $7.8M | -25% | 1.5M | 5.21 | |
| Allakos (ALLK) | 0.2 | $7.0M | -33% | 50k | 140.00 | |
| Therapeutics Acquisition Cor Com Cl A (RACA) | 0.2 | $7.0M | 500k | 13.95 | ||
| Morphic Hldg (MORF) | 0.2 | $6.7M | -20% | 200k | 33.55 | |
| Merus N V (MRUS) | 0.1 | $6.1M | -18% | 350k | 17.53 | |
| Genetron Hldgs Ads (GTH) | 0.1 | $5.6M | -20% | 400k | 14.00 | |
| Bcls Acquisition Corp Com Cl A (BLSA) | 0.1 | $5.5M | NEW | 500k | 11.03 | |
| Fs Dev Corp Com Cl A | 0.1 | $5.5M | 500k | 11.00 | ||
| 5 01 Acquisition Corp Com Cl A (FVAM) | 0.1 | $5.1M | NEW | 500k | 10.17 | |
| Eiger Biopharmaceuticals (EIGR) | 0.1 | $4.9M | -11% | 400k | 12.29 | |
| Vesper Healthcare Acqstn Cor Unit 99/99/9999 (VSPRU) | 0.1 | $4.8M | 400k | 12.12 | ||
| Replimune Group (REPL) | 0.1 | $4.8M | NEW | 125k | 38.15 | |
| Helix Acquisition Corp Com Cl A (HLXA) | 0.1 | $4.7M | NEW | 430k | 11.03 | |
| Atreca Cl A Com (BCEL) | 0.1 | $4.7M | 294k | 16.15 | ||
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $3.8M | 422k | 8.94 | ||
| Kadmon Hldgs (KDMN) | 0.1 | $3.5M | -15% | 850k | 4.15 | |
| Avrobio Ord (AVRO) | 0.1 | $3.4M | 244k | 13.94 | ||
| Panacea Acquisition Corp Unit 99/99/9999 | 0.1 | $3.2M | 250k | 12.76 | ||
| Tricida (TCDA) | 0.1 | $3.0M | -41% | 428k | 7.05 | |
| Precision Biosciences Ord (DTIL) | 0.1 | $2.9M | 347k | 8.34 | ||
| Cardiff Oncology (CRDF) | 0.1 | $2.7M | -14% | 150k | 17.99 | |
| Arena Pharmaceuticals Com New (ARNA) | 0.0 | $1.5M | -33% | 20k | 76.85 | |
| Miragen Therapeutics Com New | 0.0 | $1.5M | NEW | 93k | 16.45 | |
| Orchard Therapeutics Ads (ORTX) | 0.0 | $1.1M | 257k | 4.32 | ||
| Fate Therapeutics (FATE) | 0.0 | $909k | -33% | 10k | 90.90 | |
| Cerevel Therapeutics Hldng I *w Exp 06/09/202 (CEREW) | 0.0 | $753k | NEW | 133k | 5.65 | |
| Imv (IMV) | 0.0 | $716k | NEW | 234k | 3.05 | |
| Nektar Therapeutics (NKTR) | 0.0 | $680k | -20% | 40k | 17.00 | |
| X4 Pharmaceuticals (XFOR) | 0.0 | $669k | NEW | 104k | 6.43 | |
| Minerva Neurosciences (NERV) | 0.0 | $468k | -16% | 200k | 2.34 |
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2020 Q4 filed Feb. 16, 2021
- Cormorant Asset Management 2020 Q3 filed Nov. 16, 2020
- Cormorant Asset Management 2020 Q2 filed Aug. 14, 2020
- Cormorant Asset Management 2020 Q1 filed May 15, 2020
- Cormorant Asset Management 2019 Q4 filed Feb. 14, 2020
- Cormorant Asset Management 2019 Q3 filed Nov. 14, 2019
- Cormorant Asset Management 2019 Q2 filed Aug. 14, 2019
- Cormorant Asset Management 2019 Q1 filed May 15, 2019
- Cormorant Asset Management 2018 Q4 filed Feb. 14, 2019
- Cormorant Asset Management 2018 Q3 filed Nov. 14, 2018
- Cormorant Asset Management 2018 Q2 filed Aug. 14, 2018
- Cormorant Asset Management 2018 Q1 filed May 15, 2018
- Cormorant Asset Management 2017 Q4 filed Feb. 14, 2018
- Cormorant Asset Management 2017 Q3 filed Nov. 14, 2017
- Cormorant Asset Management 2017 Q2 filed Aug. 14, 2017
- Cormorant Asset Management 2017 Q1 filed May 15, 2017